Oxford Immunotec Global PLC (OXFD) Given Average Recommendation of “Buy” by Analysts

Oxford Immunotec Global PLC (NASDAQ:OXFD) has received a consensus rating of “Buy” from the seven research firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have given a buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $18.75.

Several equities analysts have recently commented on OXFD shares. Zacks Investment Research raised shares of Oxford Immunotec Global from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a research report on Friday, March 9th. Cowen reaffirmed a “buy” rating and set a $15.00 price target on shares of Oxford Immunotec Global in a research report on Monday, January 22nd. BTIG Research set a $21.00 price target on shares of Oxford Immunotec Global and gave the stock a “buy” rating in a research report on Monday, December 18th. BidaskClub raised shares of Oxford Immunotec Global from a “hold” rating to a “buy” rating in a research report on Wednesday. Finally, ValuEngine raised shares of Oxford Immunotec Global from a “strong sell” rating to a “sell” rating in a research report on Wednesday, March 7th.

How to Become a New Pot Stock Millionaire

Oxford Immunotec Global (NASDAQ OXFD) opened at $13.24 on Friday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 4.92 and a current ratio of 5.37. Oxford Immunotec Global has a 12-month low of $10.00 and a 12-month high of $19.51. The company has a market cap of $340.22, a PE ratio of -9.01 and a beta of -0.21.

Oxford Immunotec Global (NASDAQ:OXFD) last issued its quarterly earnings results on Tuesday, February 27th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.02. Oxford Immunotec Global had a negative net margin of 31.90% and a negative return on equity of 42.38%. The business had revenue of $25.03 million for the quarter, compared to analysts’ expectations of $25.12 million. During the same quarter last year, the company posted ($0.22) earnings per share. The company’s quarterly revenue was up 5.6% compared to the same quarter last year. research analysts forecast that Oxford Immunotec Global will post -0.9 EPS for the current fiscal year.

In other Oxford Immunotec Global news, Director Richard A. Sandberg sold 3,000 shares of the firm’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $12.01, for a total value of $36,030.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 8.11% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of OXFD. Consonance Capital Management LP bought a new position in Oxford Immunotec Global in the fourth quarter worth about $15,645,000. Perceptive Advisors LLC raised its holdings in shares of Oxford Immunotec Global by 955.1% during the third quarter. Perceptive Advisors LLC now owns 465,356 shares of the company’s stock valued at $7,818,000 after buying an additional 421,250 shares during the last quarter. Alyeska Investment Group L.P. raised its holdings in shares of Oxford Immunotec Global by 44.0% during the third quarter. Alyeska Investment Group L.P. now owns 1,355,529 shares of the company’s stock valued at $22,773,000 after buying an additional 413,904 shares during the last quarter. Redmile Group LLC raised its holdings in shares of Oxford Immunotec Global by 13.0% during the fourth quarter. Redmile Group LLC now owns 2,318,387 shares of the company’s stock valued at $32,388,000 after buying an additional 266,900 shares during the last quarter. Finally, RTW Investments LP raised its holdings in shares of Oxford Immunotec Global by 21.9% during the third quarter. RTW Investments LP now owns 1,032,370 shares of the company’s stock valued at $17,344,000 after buying an additional 185,453 shares during the last quarter. 93.31% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: This piece of content was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright legislation. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/07/oxford-immunotec-global-plc-oxfd-given-average-recommendation-of-buy-by-analysts.html.

About Oxford Immunotec Global

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply